Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Box Inc (BOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Box Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.56 (market cap $39.89B), while Box Inc trades at $28.97 (market cap $3.97B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10× Box Inc's market cap, and Box Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BOX | |
|---|---|---|
Market Cap | $39.89B | $3.97B |
Sector | Health | Technology |
52-Week High | $491.22 | $33.55 |
52-Week Low | $278.09 | $21.37 |
Enterprise Value | $38.15B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BOX trades at $28.64, down 0.56% today, with strong analyst support (17 Buy, 10 Hold, 1 Sell) and a $37.00 consensus price target representing 29% upside. The company shows robust revenue growth from $874M in 2022 to $1.09B in 2025, with net income surging to $244.62M. Recent expansion of Box Zones in Switzerland, Israel, and Singapore (Business Wire, June 30, 2026) enhances global data governance capabilities. Technical indicators show bullish moving averages but overbought RSI levels.
BOX presents a compelling growth story with expanding profitability and strategic international expansion, though elevated valuation multiples (P/E 44.75) require continued execution. Key risks include competitive cloud storage pressures and debt levels, while institutional sentiment remains positive with significant upside to price targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
